

The logo for MyCare, with "My" in a white, cursive script font and "Care" in a white, serif font, followed by a small "tm" trademark symbol.

Busulfan Therapeutic Drug Monitoring

Receive blood levels within hours instead of days

Rapid enough to provide multiple AUCs early in treatment


CE Marked and Health Canada Licensed

ASSAY HIGHLIGHTS

- Rapid, accurate, and easy to perform
- Ready for use on automated analysers already present in clinical labs
- Proprietary technology with unprecedented stability of liquid controls and calibrators
- No reagent preparation or sample pretreatment
- Validated according to FDA recognized and IVDD harmonized standards
- ISO 13485 and FDA cGMP compliant manufacturing process
- Only commercially available assay
- Cost effective

About Busulfan Testing

- Busulfan is used before hematopoietic stem cell transplantation (HSCT)¹
- HSCT is the standard treatment in various malignant diseases including leukemia (acute, chronic myeloid, acute lymphocytic), non-Hodgkin's lymphoma, Hodgkin's disease and non-malignant diseases such as metabolic diseases, immunodeficiencies, and hemoglobinopathy
- Busulfan exposure is calculated as the area under concentration-time curve (AUC)
- Optimal exposure is essential for successful hematopoietic stem cell transplantation outcomes



Patients Must Reach Target Exposure

- Busulfan dose is determined by patient's body weight
- Only 60 – 70% of patients achieve target busulfan exposure when dosed by weight²
- AUC should be between 900 and 1350 $\mu\text{M}\cdot\text{min}^3$


High exposure associated with increased risk of toxicity including:

- Mucositis
- Graft-versus-host disease
- Veno-occlusive disease (VOD)
- Transplantation-related mortality

Low exposure associated with increased risk of:

- Graft rejection
- Disease relapse

Outcomes of Busulfan Monitoring



Lower incidence of VOD:⁴

- 0 – 5% with TDM-based dose adjustment
- 24 – 75% without TDM or dose adjustment

Lower incidence of relapse 3 years post transplantation⁵

Busulfan Assay Kit

Test Parameters

Measuring Range 0 to 2,000 ng/mL
(up to 6,000 ng/mL with dilution)

Sample Type Sodium Heparin Plasma

Sample Volume 10 µL

Onboard Stability*

Reagent Stability 30 days

Calibration Stability 14 days

*Analyser Dependent

Shelf Life

Reagent 10 months


Calibrators and Controls 10 months

Stable Calibrators & Controls

A unique, patented busulfan analog in the calibrators and controls negates the need for special handling and and simplifies work flow

Method Comparison

MyCare Busulfan Assay Kit vs. GC-MS



Slope = 0.97, Y-Intercept = 18
Correlation Coefficient (r) = 0.9917, N = 208

Precision

Sample Type		Assigned Value (ng/mL)	N	Mean (ng/mL)	Repeatability	Within-Laboratory
					%CV	%CV
Controls	Low	225	80	250	4.6	6.1
	Medium	450	80	461	3.1	3.9
	High	900	80	910	1.8	2.8
Plasma	Spike 1	325	80	328	4.7	5.7
	Spike 2	600	80	615	4.0	4.8
	Spike 3	1100	80	1124	2.1	2.9
	Spike 4	1500	80	1531	2.6	3.1

Ordering Information

Order Codes

Busulfan Reagent	BSF-RGT
Busulfan Calibrators	BSF-CAL
Busulfan Controls	BSF-CON

Contact Us

To place an order:

Orders@saladax.com

Technical support:

Techsupport@saladax.com

+1 (610) 419-6731

For more information:

Hello@saladax.com

+1 (610) 419-6731

MyCareTests.com

Saladax.com

REFERENCES:

1. Bartelink, et al. 2016. Lancet Haematol; 3: e526-536
2. Palmer, et al. 2016. Biol Blood Marrow Transplant; 22: 1915-1925
3. Otsuka Pharma Co. 2015. Busulfex Package Insert
4. Grochow, et al. 1993. Semin Oncol; 20: 18-25
5. Slattery, et al. 1997. Blood; 89: 3055-3060



Saladax Biomedical
116 Research Drive
Bethlehem, PA 18015, USA